integrated, global biopharmaceutical company, announced today that one oral and five poster presentations of ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 29th Annual San Antonio Breast Cancer Symposium, December 14 - 17, 2006. The studies to be presented are intended to highlight the clinical benefits of ABRAXANE in the treatment of breast cancer. In the oral presentation, interim data will be discussed from a 300 patient, randomized, Phase II head-to-head trial of ABRAXANE versus Taxotere® (docetaxel) in the first-line treatment of metastatic breast cancer.
